SCHEMBL14360488

SCHEMBL14360488

Cc1ccccc1C1(OCCCCOCc2ccccc2)CN(OC(=O)C(F)(F)F)C1

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.37
TEAD3 Q99594 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 1/20 0.35
SPHK1 Q9NYA1 1/20 0.34
GBA1 P04062 2/20 0.33
UGCG Q16739 2/20 0.33
GBA2 Q9HCG7 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14360593 0.82 TEAD3 (0.43) L3MBTL1TEAD3MEN1GAAKMT2A
SCHEMBL14360193 0.81 L3MBTL1 (0.44) L3MBTL1TEAD3EPHX2
Trifluoroacetic Acid SCHEMBL14360485 0.81 L3MBTL1 (0.39) L3MBTL1TEAD3EPHX2
Trifluoroacetic Acid SCHEMBL14360092 0.75 MC1R (0.48) L3MBTL1
SCHEMBL1310335 0.75 PDK2 (0.34) L3MBTL1
SCHEMBL1309421 0.73 MC4R (0.38) L3MBTL1MEN1KMT2A
SCHEMBL14360222 0.70 MC1R (0.61) L3MBTL1KMT2A
SCHEMBL15212230 0.66 OPRM1 (0.40) L3MBTL1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL1309667 0.66 MC1R (0.39) L3MBTL1MEN1GAAKMT2A
SCHEMBL28571966 0.64 HDAC1 (0.68)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981952-B2 Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-05-29 US disclosed
EP-2726478-B1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2017-01-11 EP disclosed
US-20160237065-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-08-18 US disclosed
US-9353083-B2 Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-05-31 US disclosed
US-20140228342-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-08-14 US disclosed
EP-2726478-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2014-05-07 EP disclosed
WO-2013001030-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237065-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS MC1R, MCHR1, MCHR2 L3MBTL1 3785/4885TEAD3 3731/4885MEN1 1577/4885
US-20140228342-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS MC1R, MCHR1, MCHR2 L3MBTL1 3811/4885TEAD3 4064/4885MEN1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.